Literature DB >> 7055472

Hydroxychloroquine. Seven-year experience.

D R Tobin, G Krohel, R I Rynes.   

Abstract

Ninety-nine patients were treated with hydroxychloroquine sulfate for connective tissue diseases during a seven year period. All patients received the medication for at least one year and most were treated with a daily dosage of 400 mg. Four patients experienced toxic effects, but no patient sustained permanent loss of visual acuity. Toxicity did not seem to represent a cumulative dosage effect. Funduscopic and visual field examinations at six-month intervals are sufficient to detect the occasional adverse reactions and prevent serious retinal toxic effects when a maximum daily dosage of 400 mg is maintained.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7055472     DOI: 10.1001/archopht.1982.01030030083006

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  9 in total

Review 1.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

2.  Retinal disorders in northern Brazilian patients treated with chloroquine assessed by multifocal ERG.

Authors:  M Raster; F Horn; A Jünemann; A A M Rosa; G S Souza; B D Gomes; M G Lima; L C L Silveira; J Kremers
Journal:  Doc Ophthalmol       Date:  2011-02-03       Impact factor: 2.379

3.  Assessing hydroxychloroquine toxicity by the multifocal ERG.

Authors:  Michael N Moschos; Marilita M Moschos; Michael Apostolopoulos; John A Mallias; Christos Bouros; George P Theodossiadis
Journal:  Doc Ophthalmol       Date:  2004-01       Impact factor: 2.379

4.  Screening for antimalarial maculopathy in rheumatology clinics.

Authors:  B W Fleck; A L Bell; J D Mitchell; B J Thomson; N P Hurst; G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-21

5.  Detecting chloroquine retinopathy: electro-oculogram versus colour vision.

Authors:  A S Neubauer; K Samari-Kermani; U Schaller; U Welge-Lübetaen; G Rudolph; T Berninger
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

6.  Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?

Authors:  Samuel K Shinjo; Otacílio O Maia; Vivian A P Tizziani; Celso Morita; Jussara A L Kochen; Walter Y Takahashi; Ieda M M Laurindo
Journal:  Clin Rheumatol       Date:  2007-01-31       Impact factor: 3.650

7.  Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testing.

Authors:  Paradee Kunavisarut; Pimploy Chavengsaksongkram; Aniki Rothova; Kessara Pathanapitoon
Journal:  Indian J Ophthalmol       Date:  2016-10       Impact factor: 1.848

Review 8.  Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.

Authors:  Md Abdul Alim Al-Bari
Journal:  Pharmacol Res Perspect       Date:  2017-01-23

9.  Short-term, high-dose hydroxychloroquine corneal toxicity.

Authors:  Daniel E Savage; Ronald Plotnik; Rachel A F Wozniak
Journal:  Am J Ophthalmol Case Rep       Date:  2020-04-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.